Christopher Wenzinger1, Eli Williams1, Alejandro A Gru2. 1. Department of Pathology, University of Virginia, Charlottesville, VA, USA. 2. Departments of Pathology & Dermatology, University of Virginia, 415 Lane Road, Hospital Expansion Bldg Room 3024, Charlottesville, VA, 22908, USA. Aag4b@virginia.edu.
Abstract
PURPOSE OF REVIEW: Acute lymphoblastic leukemias (ALL) are malignant disorders of immature B or T cells that occur characteristically in children, usually under the age of 6 (75%). Approximately 6000 new cases of ALL are diagnosed each year in the USA, 80-85% of which represent B-ALL forms. Most presentations of B-ALL are leukemic, whereas T-ALL presents with a mediastinal mass, with or without leukemic involvement. The revised fourth edition of the World Health Organization (WHO) classification (2017) has introduced some changes in both B and T-ALL. Here, we summarize the categories of lymphoblastic leukemia/lymphomas as defined by the WHO and recent developments in the understanding of this group of hematologic malignancy. RECENT FINDINGS: Two provisional categories of B-ALL have now been identified including B-ALL, BCR-ABL1-like, and B-ALL with iAMP21. The Philadelphia chromosome-like B-ALL includes forms of the disease that shares the expression profiling of B-ALL with t(9;22) but lack such rearrangement. The second one shows amplification of part of the chromosome 21. Both entities are associated with worse prognosis. Within the T-ALL group, an early precursor T cell form has now been introduced as a provisional category. Such group demonstrates expression of stem cell and myeloid markers in conjunction with the T cell antigens. The current review summarizes the recent updates to the WHO classification.
PURPOSE OF REVIEW: Acute lymphoblastic leukemias (ALL) are malignant disorders of immature B or T cells that occur characteristically in children, usually under the age of 6 (75%). Approximately 6000 new cases of ALL are diagnosed each year in the USA, 80-85% of which represent B-ALL forms. Most presentations of B-ALL are leukemic, whereas T-ALL presents with a mediastinal mass, with or without leukemic involvement. The revised fourth edition of the World Health Organization (WHO) classification (2017) has introduced some changes in both B and T-ALL. Here, we summarize the categories of lymphoblastic leukemia/lymphomas as defined by the WHO and recent developments in the understanding of this group of hematologic malignancy. RECENT FINDINGS: Two provisional categories of B-ALL have now been identified including B-ALL, BCR-ABL1-like, and B-ALL with iAMP21. The Philadelphia chromosome-like B-ALL includes forms of the disease that shares the expression profiling of B-ALL with t(9;22) but lack such rearrangement. The second one shows amplification of part of the chromosome 21. Both entities are associated with worse prognosis. Within the T-ALL group, an early precursor T cell form has now been introduced as a provisional category. Such group demonstrates expression of stem cell and myeloid markers in conjunction with the T cell antigens. The current review summarizes the recent updates to the WHO classification.
Entities:
Keywords:
ALL; Acute leukemia; Lymphoblastic lymphoma; WHO revision
Authors: V H J van der Velden; M Brüggemann; P G Hoogeveen; M de Bie; P G Hart; T Raff; H Pfeifer; S Lüschen; T Szczepański; E R van Wering; M Kneba; J J M van Dongen Journal: Leukemia Date: 2004-12 Impact factor: 11.528
Authors: B Cauwelier; H Cavé; C Gervais; M Lessard; C Barin; C Perot; J Van den Akker; F Mugneret; C Charrin; M P Pagès; M-J Grégoire; P Jonveaux; M Lafage-Pochitaloff; M J Mozzicconacci; C Terré; I Luquet; P Cornillet-Lefebvre; B Laurence; G Plessis; C Lefebvre; D Leroux; H Antoine-Poirel; C Graux; L Mauvieux; P Heimann; C Chalas; E Clappier; B Verhasselt; Y Benoit; B D Moerloose; B Poppe; N Van Roy; K D Keersmaecker; J Cools; F Sigaux; J Soulier; A Hagemeijer; A D Paepe; N Dastugue; R Berger; F Speleman Journal: Leukemia Date: 2006-10-12 Impact factor: 11.528
Authors: Elaine Coustan-Smith; Charles G Mullighan; Mihaela Onciu; Frederick G Behm; Susana C Raimondi; Deqing Pei; Cheng Cheng; Xiaoping Su; Jeffrey E Rubnitz; Giuseppe Basso; Andrea Biondi; Ching-Hon Pui; James R Downing; Dario Campana Journal: Lancet Oncol Date: 2009-01-13 Impact factor: 41.316
Authors: Kelly W Maloney; Jeffrey W Taub; Yaddanapudi Ravindranath; Irene Roberts; Paresh Vyas Journal: Pediatr Clin North Am Date: 2015-02 Impact factor: 3.278
Authors: Hua Yin; Mei Hong; Jun Deng; Lan Yao; Chenjing Qian; Yao Teng; Tingting Li; Qiuling Wu Journal: Front Oncol Date: 2022-02-24 Impact factor: 6.244